Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -247 | -154 | -132 | -62 | 27 |
| Depreciation Amortization | 53 | 31 | 21 | 11 | 41 |
| Accounts receivable | 10 | -4 | -2 | -4 | 106 |
| Accounts payable and accrued liabilities | -31 | -36 | 2 | 1 | -464 |
| Other Working Capital | -24 | -36 | 9 | 2 | -341 |
| Other Operating Activity | 21 | 40 | 0 | 3 | 358 |
| Operating Cash Flow | $-217 | $-159 | $-102 | $-49 | $-274 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | -6 | -9 | -15 | -40 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -12 |
| Investing Cash Flow | $-13 | $-6 | $-9 | $-15 | $-52 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -17 | -14 | -8 | -4 | N/A |
| Common Stock Issued | -163 | -93 | N/A | N/A | 742 |
| Other Financing Activity | -1 | -1 | -1 | 0 | 2 |
| Financing Cash Flow | $-181 | $-107 | $-9 | $-4 | $743 |
| Exchange Rate Effect | 10 | -11 | -1 | 20 | 4 |
| Beginning Cash Position | 1,260 | 1,260 | 1,260 | 1,260 | 839 |
| End Cash Position | 859 | 977 | 1,140 | 1,213 | 1,260 |
| Net Cash Flow | $-401 | $-283 | $-120 | $-47 | $421 |
| Free Cash Flow | |||||
| Operating Cash Flow | -217 | -159 | -102 | -49 | -274 |
| Capital Expenditure | -13 | -6 | -9 | -15 | -40 |
| Free Cash Flow | -230 | -165 | -111 | -63 | -314 |